Nurix Therapeutics Inc (NRIX)
15.40
-0.50
(-3.14%)
USD |
NASDAQ |
May 16, 16:00
15.38
-0.02
(-0.10%)
After-Hours: 20:00
Nurix Therapeutics Enterprise Value: 696.45M for May 16, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 16, 2024 | 696.45M |
| May 15, 2024 | 726.98M |
| May 14, 2024 | 668.97M |
| May 13, 2024 | 607.29M |
| May 10, 2024 | 581.03M |
| May 09, 2024 | 607.90M |
| May 08, 2024 | 609.73M |
| May 07, 2024 | 620.72M |
| May 06, 2024 | 563.32M |
| May 03, 2024 | 536.45M |
| May 02, 2024 | 533.40M |
| May 01, 2024 | 554.77M |
| April 30, 2024 | 490.04M |
| April 29, 2024 | 517.52M |
| April 26, 2024 | 510.80M |
| April 25, 2024 | 510.80M |
| April 24, 2024 | 595.69M |
| April 23, 2024 | 618.89M |
| April 22, 2024 | 585.30M |
| April 19, 2024 | 585.91M |
| April 18, 2024 | 637.82M |
| April 17, 2024 | 615.84M |
| April 16, 2024 | 650.65M |
| April 15, 2024 | 515.88M |
| April 12, 2024 | 578.79M |
| Date | Value |
|---|---|
| April 11, 2024 | 601.89M |
| April 10, 2024 | 527.18M |
| April 09, 2024 | 615.16M |
| April 08, 2024 | 434.29M |
| April 05, 2024 | 439.20M |
| April 04, 2024 | 441.17M |
| April 03, 2024 | 473.12M |
| April 02, 2024 | 486.39M |
| April 01, 2024 | 472.63M |
| March 28, 2024 | 478.52M |
| March 27, 2024 | 470.66M |
| March 26, 2024 | 395.95M |
| March 25, 2024 | 421.02M |
| March 22, 2024 | 415.61M |
| March 21, 2024 | 395.95M |
| March 20, 2024 | 408.55M |
| March 19, 2024 | 382.01M |
| March 18, 2024 | 386.93M |
| March 15, 2024 | 398.72M |
| March 14, 2024 | 445.89M |
| March 13, 2024 | 467.51M |
| March 12, 2024 | 462.60M |
| March 11, 2024 | 450.31M |
| March 08, 2024 | 485.69M |
| March 07, 2024 | 468.49M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-52.71M
Minimum
Oct 25 2023
1.734B
Maximum
Mar 17 2021
547.94M
Average
427.64M
Median
Aug 01 2022
Enterprise Value Benchmarks
| Gilead Sciences Inc | 104.94B |
| ALX Oncology Holdings Inc | 616.05M |
| Vanda Pharmaceuticals Inc | -69.40M |
| GlycoMimetics Inc | -13.16M |
| Immunic Inc | 15.29M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -41.52M |
| Revenue (Quarterly) | 16.58M |
| Total Expenses (Quarterly) | 61.80M |
| EPS Diluted (Quarterly) | -0.76 |
| Profit Margin (Quarterly) | -250.3% |
| Earnings Yield | -17.27% |
| Normalized Earnings Yield | -17.27 |